|Table of Contents|

Clinical significance of high-risk HPV testing for cervical precancerous lesions and cervical cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 05
Page:
788-791
Research Field:
Publishing date:

Info

Title:
Clinical significance of high-risk HPV testing for cervical precancerous lesions and cervical cancer
Author(s):
Zhang Qin; Wang Dong
Gynecological Oncology Center，Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital，Chongqing 400030，China.
Keywords:
human papillomavirus; precancerous lesion; LSIL; HSIL; cervical cancer
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2020.05.021
Abstract:
Objective：To provide a theoretical basis for the screening of cervical lesions and HPV vaccines selection，we analyzed the relationship of high-risk HPV infection in the development and progression of cervical precancerous lesions and cervical cancer.Methods：1 197 patients from the gynecological oncology center of our hospital were chosen.According to the pathologic examination result，the patients were divided into chronic cervicitis group (212 cases)，LSIL group (142 cases)，HSIL group (484 cases) and cervical cancer group (359 cases).Then the infection of high-risk HPV in each group was detected.We analyzed the positive rate of HPV and the distribution of HPV subtypes in each group.Results：The positive rate of HPV infection was 9.43% in chronic cervicitis group，78.87% in LSIL group，92.15% in HSIL group and 97.77% in cervical cancer group.There was significant difference in the positive rate between the two groups (P<0.001).In each group，the single infection rate of high-risk HPV was higher than the multiple infection rate，and the difference was statistically significant (P＜0.001).HPV52，HPV16 and HPV58 were the main subtypes in chronic cervicitis group,and the positive rates were 3.77%，2.83% and 1.41%，respectively.HPV52，HPV16 and HPV58 were the main subtypes in LSIL group,and the positive rates were 23.94%，21.13% and 16.90%，respectively.HPV16，HPV52 and HPV58 were the main subtypes in HSIL group,and the positive rates were 33.06%，29.34% and 19.42%，respectively.HPV16，HPV58 and HPV52 were the main subtypes in cervical cancer group,and the positive rates were 65.18%，20.89% and 10.86%,respectively.HPV16，HPV18，HPV33，HPV52 and HPV58 were the five subtypes with the highest infection rate among HSIL and cervical cancer population in this region.Conclusion：The more severe the degree of cervical lesions,the higher HPV positive rate.Each degree of cervical lesion has different HPV subtypes.High-risk HPV detection has important guiding significance for early screening of cervical lesions and vaccination of HPV vaccine in local population.

References:

［1］GU XY，ZHENG RS，SUN KX，et al.Incidence and mortality of cervical cancer in China，2014［J］.Chin J Oncol，2018，40(4)：241-246.［顾秀瑛，郑荣寿，孙可欣，等.2014年中国女性子宫颈癌发病与死亡分析［J］.中华肿瘤杂志，2018，40(4)：241-246.］
[2]TIAN LJ，WU SH，LI X，et al.Advances in the research of HPV and cervical cancer and precancerous lesions［J］.Journal of Chinese Physician，2017，19(9)：1437-1440.［田凌君，吴素慧，李雪，等.HPV与宫颈癌及癌前病变的研究进展［J］.中国医师杂志，2017，19(9)：1437-1440.］
[3]Maria TS，Daniela R，Michela S，et al.Typing of human papillomavirus in women with cervical lesions：Prevalence and distribution of different genotypes［J］.Journal of Medical Virology，2009，81(2)：271-277.
[4]Zhao XL，Hu SY，Zhang Q，et al.High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population［J］.Journal of Gynecologic Oncology，2017，28(4)：1-11.
[5]Basu P，Mittal S，Bhadra Vale D，et al.Secondary prevention of cervical cancer［J］.Best Practice Research Clinical Obstetrics Gynaecology，2018（47）：73-85.
[6]Mette T，Bodil H，BechJan B，et al.Preventing cervical cancer using HPV self-sampling：Direct mailing of test-kits increases screening participation more than timely opt-in procedures-a randomized controlled trial［J］.BMC Cancer，2018（18）：273-278.
[7]Mariel M，Antonio H，Frecia G，et al.Understanding the HPV integration and its progression to cervical cancer［J］.Infection，Genetics and Evolution，2018(61)：134-144.
[8]Burk RD，Chen Z，Saller C，et al.Integrated genomic and molecular characterization of cervical cancer［J］.Nature，2017，543(7645)：378-384.
[9]Gina SO，Mel K，Dirk VN，et al.HPV for cervical cancer screening (HPV FOCAL)：Complete round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer［J］.Int J Cancer，2017，140(2)：440-448.
[10]ZHANG J，LIU XY，GAN L，et al.The significance of HPV genotypes in cervical cancer screening［J］.Modern Oncology，2016，24(14)：2293-2296.［张静，刘晓英，甘露，等.HPV分型研究在宫颈癌筛查中的意义［J］.现代肿瘤医学，2016，24(14)：2293-2296.］
[11]Liang H，Fu M，Zhou J，et al.Evaluation of 3D-CPA，HR-HPV，and TCT joint detection on cervical disease screening［J］.Oncology Letters，2016，12(2)：887-892.
[12]Mittal S，Basu P，Muwonge R，et al.Risk of high-grade precancerous lesions and invasive cancers in high-risk HPV-positive women with normal cervix or CIN 1 at baseline-A population-based cohort study［J］.Int J Cancer，2017，140(8)：1850-1859.
[13]Ge Y，Zhong S，Ren M，et al.Prevalence of human papillomavirus infection of 65，613 women in East China［J］.BMC Public Health，2019，19(1)：178-182.
[14]Rana AA，Nawaf AM，Ahmed N，et al.Association of HPV genotypes with external anogenital warts：A cross sectional study［J］.BMC Infectious Disease，2019(19)：375-380.
[15]Li M，Du X，Lu M，et al.Prevalence characteristics of single and multiple HPV infections in women with cervical cancer and precancerous lesions in Beijing［J］.Journal of Medical Virology，2019，91(3)：473-481.
[16]DUAN E.Meta-analysis of distribution of human papillomavirus types in Chinese women［［J］.International Medicine and Health Guidance News，2017，23(1)：18-21.［段娥.人乳头瘤病毒在中国大陆女性的型别分布的Meta分析［J］.国际医药卫生导报，2017，23(1)：18-21.］
[17]Lauri E，Markowitz，Susan H，et al.Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States，national health and nutrition examination surveys 2003-2010［J］.The Journal of Infectious Diseases，2013，208(3)：385-393.
[18]Torre G，Waure C，Chiaradia G，et al.HPV vaccine efficacy in preventing persistent cervical HPV infection：A systematic review and meta-analysis［J］.Vaccine，2007，25(50)：8352-8358.

Memo

Memo:
重庆市科委社会发展领域科技项目（编号：cstc2016shmszx130062）
Last Update: 1900-01-01